A germline pathogenic variant (in BRCA1, BRCA2, PALB2, CHEK2, ATM, RAD51C, BARD1, PMS2, or MSH6) was identified in 31 of 474 women (6.5%), including 28 of 429 women with invasive breast cancer (6.5%) (Supporting Information, table). This evidence concerns the gene BARD1 and invasive breast carcinoma.